Cureline Group’s Full Range of Research Services Now Available Through Scientist.com
25.7.2023 14:55:00 EEST | Business Wire | Press release
Cureline Group, an industry pioneer in precision and translational medicine, today announced its plans to showcase its full spectrum of research products and services on Scientist.com, the premier preclinical research marketplace for the biopharma sector. Biopharma researchers utilizing Scientist.com can now quickly and economically access essential services such as biobanking (including collection, processing, storage and retrieval of biological samples), human sample validation (including biomarker identification and verification), preclinical animal services and preclinical project management (protocol design, study execution and data analysis), histopathology, digital pathology and other lab services that are critical to accelerating drug discovery and development.
“We are excited to continue our longstanding partnership with Scientist.com, which has helped us connect with many biopharma researchers at top pharma and biotech companies,” stated Dr. Olga Potapova, Founder and CEO of the Cureline Group. “With our 20 years of translational CRO experience, we want to make it easy for any industry or academic scientist to access the many innovative tools and technologies and regulatory expertise that we’ve brought together under one roof.”
The Cureline Group, comprised of an array of companies including Cureline, Inc., Cureline BioPathology (CBP), Cureline Molecular Services (CMS), Cureline Baltic UAB, DolceRx Baltika UAB and the newly formed Memel Biotech, offers an extensive portfolio of ISO-certified, CAP-compliant preclinical research and biomarker/companion diagnostics services. Clinical expertise will be delivered by the recent strategic partnership of palleos healthcare (Germany) and Cureline. Offering clients a full-service approach can help reduce complexity and save time.
“The Cureline Group has evolved into a one-stop shop for high-quality research services in the preclinical research and biomarker/companion diagnostic spaces,” stated Kevin Lustig, PhD, Founder and CEO at Scientist.com. "We are delighted to feature their services on Scientist.com’s fast-growing, AI-powered marketplace."
About Cureline, Inc., and the Cureline Group of companies:
As a global leader in commercial biobanking and translational research services celebrating 20 years in business in 2023, we have completed over 5,000 projects for 850 clients. Cureline, Inc., (USA) together with other Cureline Group companies, is a global precision and translational medicine contract research organization (CRO) providing biobanking and HBS services in the preclinical phase and companion diagnostics development for clinical trials to the biopharmaceutical industry. Cureline Group management are experts in global regulatory affairs, custom protocol biobanking, histopathology & digital pathology, molecular and cellular lab services, small animal studies and cell and gene therapy (ATMP) solutions. Since 2021, UAB Cureline Baltic (Lithuania) is servicing our clients' needs in animal toxicology and preclinical efficacy studies in small animals with a focus on metastatic cancer, immunology and microbiota models. Starting in 2024, Memel Biotech UAB (Lithuania) will be providing GMP CDMO service for the ATMP clinical research community.
Visit http://www.cureline.com/ to learn more.
About Scientist.com
Scientist.com's mission is to empower and connect scientists worldwide. The company's AI-powered research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.
Visit Scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram
About palleos healthcare GmbH
palleos healthcare is a full-service CRO with 50 highly experienced employees covering Phase I – IV drug and medical device clinical research services in central Europe. More than 10,000 patients at 300 sites were treated in various trials and indications with the results published in highly ranked journals. palleos healthcare also offers drug development consulting services for biotech and medtech companies, streamlining their early and pre-clinical development decisive milestones, allowing earlier and more efficient exit and reinvestment. As a certified partner with best-in-class players in the digital life science field (Veeva, Medidata, etc.), palleos healthcare offers cloud-based services for data management and decentralized clinical trials.
Visit www.palleos.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230725851885/en/
Contact information
Media Contact:
Olga Potapova, CEO, The Cureline Group
+1 415-468-6400 ext. 221
olga-potapova@cureline.com
Sean Preci, Sr. Director, Marketing & Content, Scientist.com
+1 858 771-3813 ext. 187
marketing@scientist.com
Heiko Bergmann, VP Sales & Strategy, palleos healthcare GmbH
+49 611 950 190 0 ext. 50
heiko.bergmann@palleos.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology16.6.2026 20:00:00 EEST | Press release
Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries. On June 10, 2026, the UPC determined that Siemens infringed upon European Patent EP 2 352 431, Hologic’s Focusing Technology on the Envision™ Platform, the first FDA-approved mammography innovation of its kind.1 In addition to the broad injunction against Siemens, recall and destruction of infringing systems, Hologic will rec
RealTime Reservation Acquires STAY to Create Leading Global Guest Experience Platform Serving 2,000+ Properties Across 75+ Countries16.6.2026 19:30:00 EEST | Press release
RealTime Reservation (RTR), the industry leader in dynamic hospitality booking technology for onsite activities, amenities, and ancillary revenue management, today announced its acquisition of STAY, creating a global end-to-end guest experience platform for the hospitality industry. The combined company will serve more than 2,000 hospitality properties across 75+ countries throughout North America, Europe, Latin America and the Caribbean. The combination significantly expands RTR's international footprint and strengthens its position as a leading provider of guest engagement, ancillary revenue, and guest experience technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616258776/en/ Pictured: RealTime Reservation's dynamic booking interface allows hotel guests to select and reserve pool and beach amenities by location, date, and availability, streamlining ancillary revenue management for properties of any size. Courte
Happy Holidays S.A. and JTA Investment Holding Announce €65 Million Investment for SARTIMARE Tourism Development in Greece16.6.2026 18:42:00 EEST | Press release
Happy Holidays S.A. today announced the signing of an Investment Agreement with Qatar-based JTA Investment Holding for the development of the sustainable SARTIMARE Beach Resort & Spa project in Sarti, Halkidiki, Greece. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616892834/en/ Dr. Amir Ali Salemi Zadeh, CEO of JTA Investment Holding and Georgios Iosifidis, Founder & Owner of Happy Holidays S.A. Under the agreement, JTA Investment Holding will invest €65 million into the development. The project will be built on a site of approximately 120,900 square meters, with construction scheduled between 2027 and 2030. Designed with a strong commitment to environmental responsibility, the SARTIMARE project will feature luxury hospitality facilities, premium residences and villas, wellness amenities, retail, food & beverage outlets, and marina infrastructure. The project's valuation is expected to exceed €100 million as key develop
IFF and ISIPCA Mark 10 Years of Joint Scent Design and Creation Master’s-Level Program16.6.2026 18:00:00 EEST | Press release
IFF — a global leader in flavors, fragrances, food ingredients and health & biosciences — celebrates the 10th anniversary of its industry-leading accredited master's-level program for scent design and creation, developed in partnership with ISIPCA, the world-renowned school for careers in perfume, cosmetics and food flavors. Since its launch in 2016, the IFF ISIPCA program has trained more than 180 professionals from 40 countries, with 130 graduates to date, and a 100% job landing rate up to six months after graduation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615461626/en/ The IFF ISIPCA Scent Design and Creation program has been pioneering fragrance education and excellence since 2016. “Over the past decade, IFF ISIPCA has built a strong pipeline of diverse, high-potential fragrance experts, combining creative excellence, scientific expertise and a global perspective,” says Valery Claude, program sponsor and senio
Fenchurch Advisory Partners to Combine With Broadhaven Capital Partners, Creating the Preeminent International Investment Bank Serving the Financial Services Sector16.6.2026 17:30:00 EEST | Press release
Fenchurch Advisory Partners has entered into a definitive agreement to combine with Broadhaven Capital Partners, a leading independent advisory firm to the financial technology and financial services sectors in North America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616214669/en/ Fenchurch is one of the most respected investment banking advisory firms dedicated exclusively to the financial services sector. With offices in London, New York and Paris, Fenchurch provides trusted, independent advice to corporates and financial sponsors across insurance, asset and wealth management, banking, and specialty finance. In 2025, Fenchurch advised on 27 transactions, ranking as the number one adviser to the financial services sector in the UK and Europe. Founded in 2009, Broadhaven has established itself as a premier investment bank advising corporates and financial sponsors on M&A, capital raising, and strategic transactions,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom